미국의 저분자 Drug Discovery 아웃소싱 시장 규모, 점유율, 동향 분석 보고서 : 워크플로우별, 서비스별, 치료 영역별, 최종 용도별, 부문 예측(2025-2033년)

U.S. Small Molecule Drug Discovery Outsourcing Market Summary

The U.S. small molecule drug discovery outsourcing market size was estimated at USD 1.52 billion in 2024 and is projected to reach USD 3.47 billion by 2033, growing at a CAGR of 9.7% from 2025 to 2033. Increasing R&D expenses, rising focus on early-stage research activities, and growing biotech companies with limited in-house resources drive the market.

Besides, outsourcing has emerged as a strategic option for pharmaceutical and biotech companies aiming to accelerate the timelines, lower fixed overhead costs, and gain access to specialized expertise in areas such as medicinal chemistry, hit-to-lead optimization, ADME/PK studies, and IND-enabling activities.

Innovations like AI-driven compound design, CRISPR-based target validation, high-throughput screening, and 3D cell models transform discovery processes, enabling contract research organizations (CROs) to provide more efficient and predictive results. Furthermore, rising R&D costs, increased demand for drug development, and a shift towards virtual pharmaceutical models support the market. In addition, an increase in registered clinical studies, a higher approval rate for small molecule drugs, advancements in medical technology, a rise in diseases being studied, and the urgent need for new treatments are anticipated to drive the market.

U.S. Small Molecule Drug Discovery Outsourcing Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. small molecule drug discovery outsourcing market report based on workflow, service, therapeutics area, and end use:

• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Target Identification & Screening
• Target Validation & Functional Informatics
• Lead Identification & Candidate Optimization
• Preclinical Development
• Others
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Chemistry Services
• Biology Services
• Therapeutics Area Outlook (Revenue, USD Million, 2021 - 2033)
• Respiratory system
• Pain and Anesthesia
• Oncology
• Ophthalmology
• Hematology
• Cardiovascular
• Endocrine
• Gastrointestinal
• Immunomodulation
• Anti-infective
• Central Nervous System
• Dermatology
• Genitourinary System
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biotechnology companies
• Academic Institutes

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Workflow
  • 1.2.2. Service
  • 1.2.3. Therapeutics Area
  • 1.2.4. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Value chain-based analysis (Model 2)
  • 1.7.3. Multivariate Analysis (Model 3)
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Small Molecule Drug Discovery Outsourcing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing demand for outsourcing services in drug development
    • 3.2.1.2. Technological advancements in drug discovery
    • 3.2.1.3. Rising shortening time-to-market pressures
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Intellectual property (IP) and data security concerns
    • 3.2.2.2. Limited standardization and reproducibility
• 3.3. Clinical Trials Volume Analysis, (2024)
  • 3.3.1. Total Number Of Clinical Trials By Country
  • 3.3.2. Total Number Of Clinical Trials, By Phase
  • 3.3.3. Total Number Of Clinical Trials, By Study Design
  • 3.3.4. Total Number Of Clinical Trials, By Key Therapeutic Area
• 3.4. Pricing Model Analysis
• 3.5. Technology Landscape
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL by SWOT Analysis

Chapter 4. U.S. Small Molecule Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis

• 4.1. U.S. Small Molecule Drug Discovery Outsourcing Market, By Workflow: Segment Dashboard
• 4.2. U.S. Small Molecule Drug Discovery Outsourcing Market, By Workflow: Movement Analysis
• 4.3. U.S. Small Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
• 4.4. Target Identification & Screening
  • 4.4.1. Target Identification & Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Target Validation & Functional Informatics
  • 4.5.1. Target Validation & Functional Informatics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Lead Identification & Candidate Optimization
  • 4.6.1. Lead Identification & Candidate Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Preclinical Development
  • 4.7.1. Preclinical Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Small Molecule Drug Discovery Outsourcing Market: Service Estimates & Trend Analysis

• 5.1. U.S. Small Molecule Drug Discovery Outsourcing Market, By Service: Segment Dashboard
• 5.2. U.S. Small Molecule Drug Discovery Outsourcing Market, By Service: Movement Analysis
• 5.3. U.S. Small Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
• 5.4. Chemistry Services
  • 5.4.1. Chemistry Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Biology Services
  • 5.5.1. Biology Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Small Molecule Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis

• 6.1. U.S. Small Molecule Drug Discovery Outsourcing Market, By Therapeutics Area: Segment Dashboard
• 6.2. U.S. Small Molecule Drug Discovery Outsourcing Market, By Therapeutics Area: Movement Analysis
• 6.3. U.S. Small Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Therapeutics Area, 2021 - 2033 (USD Million)
• 6.4. Respiratory system
  • 6.4.1. Respiratory System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Pain and Anesthesia
  • 6.5.1. Pain and Anesthesia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Oncology
  • 6.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Ophthalmology
  • 6.7.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Hematology
  • 6.8.1. Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.9. Cardiovascular
  • 6.9.1. Cardiovascular Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.10. Endocrine
  • 6.10.1. Endocrine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.11. Gastrointestinal
  • 6.11.1. Gastrointestinal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.12. Immunomodulation
  • 6.12.1. Immunomodulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.13. Anti-infective
  • 6.13.1. Anti-infective Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.14. Central Nervous System
  • 6.14.1. Central Nervous System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.15. Dermatology
  • 6.15.1. Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.16. Genitourinary System
  • 6.16.1. Genitourinary System Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Small Molecule Drug Discovery Outsourcing Market: End Use Estimates & Trend Analysis

• 7.1. U.S. Small Molecule Drug Discovery Outsourcing Market, By End Use: Segment Dashboard
• 7.2. U.S. Small Molecule Drug Discovery Outsourcing Market, By End Use: Movement Analysis
• 7.3. U.S. Small Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
• 7.4. Pharmaceutical & Biotechnology companies
  • 7.4.1. Pharmaceutical & Biotechnology companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Academic Institutes
  • 7.5.1. Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
  • 8.1.1. Market Leaders
  • 8.1.2. Emerging Players
• 8.2. Company Market Share/Assessment Analysis, 2024
• 8.3. Company Profiles
  • 8.3.1. Charles River Laboratories
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Laboratory Corporation of America Holdings (Covance)
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Albany Molecular Research (Curia)
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Merck & Co., Inc.
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. QIAGEN
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Eurofins
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Evotec
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. GenScript Biotech
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Pharmaron
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. Syngene International
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Service Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. Dalton Pharma Services
    • 8.3.11.1. Company Overview
    • 8.3.11.2. Financial Performance
    • 8.3.11.3. Service Benchmarking
    • 8.3.11.4. Strategic Initiatives
  • 8.3.12. Oncodesign
    • 8.3.12.1. Company Overview
    • 8.3.12.2. Financial Performance
    • 8.3.12.3. Service Benchmarking
    • 8.3.12.4. Strategic Initiatives
  • 8.3.13. Jubilant Biosys
    • 8.3.13.1. Company Overview
    • 8.3.13.2. Financial Performance
    • 8.3.13.3. Service Benchmarking
    • 8.3.13.4. Strategic Initiatives
  • 8.3.14. Domainex
    • 8.3.14.1. Company Overview
    • 8.3.14.2. Financial Performance
    • 8.3.14.3. Service Benchmarking
    • 8.3.14.4. Strategic Initiatives
  • 8.3.15. Dr. Reddy Laboratories Ltd.
    • 8.3.15.1. Company Overview
    • 8.3.15.2. Financial Performance
    • 8.3.15.3. Service Benchmarking
    • 8.3.15.4. Strategic Initiatives
  • 8.3.16. Pharmaron Beijing Co., Ltd.
    • 8.3.16.1. Company Overview
    • 8.3.16.2. Financial Performance
    • 8.3.16.3. Service Benchmarking
    • 8.3.16.4. Strategic Initiatives
  • 8.3.17. TCG Lifesciences Pvt Ltd.
    • 8.3.17.1. Company Overview
    • 8.3.17.2. Financial Performance
    • 8.3.17.3. Service Benchmarking
    • 8.3.17.4. Strategic Initiatives

Chapter 9. Key Recommendations